"instanceType","label","id","rationale","name","description","uuid:ID"
"StudyDesign","","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1","The main design for the study","3f1ff0c7-49b2-4c18-82d1-b049e7137504"
